MedTrace Logo

Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses

NCT03620032 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2023-12-06

No results posted yet for this study

Summary

Prospective, non-blinded, randomised two cohorts study on the efficacy of two different radiotherapy schedule for DIPG by using the same concomitant and post-radiotherapy systemic treatment.

Conditions

  • Diffuse Intrinsic Pontine Glioma

Interventions

DRUG

Nimotuzumab

humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)

DRUG

Vinorelbine

Chemotherapy

OTHER

Radiotherapy

RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS

Sponsors & Collaborators

  • University of Roma La Sapienza

    collaborator OTHER

  • Johannes Gutenberg University Mainz

    collaborator OTHER

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    collaborator OTHER

  • Wuerzburg University Hospital

    collaborator OTHER

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Principal Investigators

  • Maura Massimino, MD · Fondazione IRCCS ISTITUTO NAZIONALE TUMORI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-02
Primary Completion
2022-11-11
Completion
2024-11-02

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620032 on ClinicalTrials.gov